BioIVT

Activities: Research & Development

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

BioIVT acquires supplier of "human biological material" for in vitro

PrecisionMed is a leading supplier of high-quality human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics
Research & Development

BioIVT acquires Fidelis Research

The transaction increases BioIVT's network and allows it to extends to deliver fresh biospecimens and produce cell products for drug and diagnostic development
Research & Development

BioIVT acquires Cypex, a leading manufacturer of drug-metabolising enzymes

Cypex’s recombinant xenobiotic metabolising enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development
Research & Development

BioIVT appoints Senior VP, Global Commercial Operations

Jennifer Murphy has more than 16 years’ experience in the diagnostics and life sciences industries
Research & Development

BioIVT hosting open house at London blood donor centre

The company’s Wood Lane location has expanded apheresis, whole blood, and plasma collection capabilities, as well as an on-site cell isolation laboratory

BioIVT appoints new COO

Lori Ball will move from her role as President and CEO of LAB Strategies take up the role at the provider of research models and services for drug and diagnostic development
Research & Development

Study uses fresh method to evaluate botanical-drug interactions

A whole cell model using Transporter-certified hepatocytes in sandwich culture has demonstrated that false positives might be a risk with the traditional method of analysis
Subscribe now